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Cutis laxa (CL) is a heterogeneous group of genetic and acquired disorders with at least two autosomal dominant
forms caused by mutations in the elastin and ﬁbulin-5 genes, respectively. To deﬁne the molecular basis of CL in
patients negative for point mutations in the elastin gene, metabolic labeling and immunoprecipitation experiments
were used to study the synthesis of elastin in dermal ﬁbroblasts. In addition to the normal 68 kDa tropoelastin (TE)
protein, an abnormal, 120 kDa polypeptide was detected in the proband and her affected daughter in a CL family
characterized by hernias and unusually severe and early-onset pulmonary disease including bronchiectasis and
pulmonary emphysema. Mutational and gene expression studies established that affected individuals in this family
carried a partial tandem duplication in the elastin locus. Immunoprecipitation experiments showed that the mutant
TE was partially secreted and partially retained intracellularly. A polyclonal antibody raised against a unique
peptide in the mutant TE molecule showed both intracellular and matrix staining. We conclude that elastin mu-
tations can cause CL associated with a severe pulmonary phenotype. Synthesis of abnormal TE may interfere with
elastic ﬁber function through a dominant-negative or a gain of function mechanism.
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Cutis laxa (CL) is an inherited or acquired connective tissue
disorder characterized by redundant, loose, sagging, and
inelastic skin. An abnormal deficiency of dermal elastic fib-
ers or reduced elastin synthesis of cultured CL fibroblasts
has been previously demonstrated (Olsen et al, 1988; Se-
phel et al, 1989).
Autosomal dominant CL (ADCL, OMIM 123700) is usually
a mild cutaneous disease (Beighton, 1972), sometimes ac-
companied by gastrointestinal diverticuli, hernias, or genital
prolapse (Damkier et al, 1991). Pulmonary artery stenosis,
aortic, and arterial dilatation and tortuosity, Raynaud’s phe-
nomenon (Hayden et al, 1968; Weir et al, 1977; Tsuji et al,
1990; Tassabehji et al, 1998), bronchiectasis (Beighton,
1972), and emphysema (Corbett et al, 1994) are rare com-
plications. Two previous studies have shown mutations in
the elastin gene (ELN) in ADCL patients (Tassabehji et al,
1998; Zhang et al, 1999).
Little is known about the molecular pathology of ADCL.
The three mutations described in ADCL patients, to date,
were all single nucleotide deletions at the 30-end of ELN
(Tassabehji et al, 1998; Zhang et al, 1999). One mutation
was expressed in dermal fibroblasts (Tassabehji et al, 1998),
whereas the others were reported to disrupt mRNA stability
(Zhang et al, 1999). We have recently studied a CL family,
characterized by particularly severe pulmonary disease. In
this family, we identified a tandem duplication of ELN that
led to the synthesis of a mutant protein, which was partially
retained intracellularly and also partially secreted and in-
corporated into elastic fibers. Thus, results from our study
demonstrated that synthesis of abnormal tropoelastin (TE)
contributes to the pathogenesis of ADCL.
Results
A detailed description of the proband (III.1, Fig 1A,B) and
her daughter (IV.4, Fig 1B,C) was provided in two previous
reports (Beighton, 1972; Corbett et al, 1994). The following
description of the family is based on our own (F. M. P.) in-
terview and collection of clinical information from the family
and has been recently updated. III.1 had early, generalized
CL. Her skin laxity and associated facial features including
sagging facial skin and ears, hooked nose, everted nostrils,
and long philtrum progressively worsened during childhood,
necessitating a facial plastic surgery at the age of 6. Despite
the surgery, facial features reappeared in adolescence and
progressively worsened during adulthood (Fig 1A). Her res-
piratory symptoms began in childhood and following fre-
quent chest infections, bronchiectasis was confirmed by
bronchography at 21 y of age. At 29, an inguinal hernia was
diagnosed. By the age of 36 y, emphysema was confirmed
1These two authors, listed in alphabetical order, contributed
equally to this work.
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(Fig 1C), as was an a-1 antitrypsin M/Z genotype. Emphy-
sema in III.1 was progressive and aggravated by heavy
intermittent cigarette smoking. Steady deterioration of res-
piratory function (pre-transplant forced expiratory volume in
1 s (FEV1)¼ 0.36, 17% predicted) (Corbett et al, 1994) cul-
minated in end-stage respiratory failure with right-heart fail-
ure, hypercapnia, hypoxemia, and respiratory acidosis.
Consequently, at the age of 51 y, she received a double
lung transplant, followed by routine immunosuppression
with cyclosporine and azothioprine. She died at the age of
61 y because of renal failure associated with immunosup-
pressant treatment.
After one normal pregnancy and two miscarriages, at the
age of 29, a daughter (IV.4) was born to III.1 with obvious
congenital CL (Fig 1D). Between 6 and 18 mo of age,
systolic heart murmur caused by a small ventricular septal
defect was noted (Beighton, 1972). At 23 y, lung function
tests indicated signs of emphysema (FEV1¼ 2.04, 62%
predicted). IV.4 was also an a-1 antitrypsin M/Z heterozy-
gote and a smoker at the time (Corbett et al, 1994). But, she
declined regular clinical evaluation. The mother (II.5) of III.1
had congenital CL and later developed an inguinal hernia,
uterine prolapse, dyspnea, and bronchiectasis (Beighton,
1972). In addition, the maternal grandmother (I.2), the ma-
ternal uncle (II.9), and a cousin (III.11) of III.1 were allegedly
affected by CL but these individuals were not available for
examination (Fig 1B).
Elastic staining of skin biopsy sections from III.1 revealed
a normal quantity, but abnormal morphology of elastic fibers
with metachromasia after hematoxylin–eosin staining
(Fig 2A), and fragmented and clumped appearance (Fig
2A,B), especially in the upper dermis (Fig 2B). Electron mi-
croscopic evaluation of dermal elastic fibers showed a lack
of association of elastin with peripheral microfibrils and ab-
errant branching and clubbing (Fig 2D). Similar abnormalities
were noted on a bronchial biopsy specimen (not shown).
To search for disease-causing alleles CL-1, exon-by-
exon direct sequence analysis of genomic amplimers in the
elastin gene was completed in patient III.1 (not shown). No
mutations were identified. Metabolic labeling and immuno-
precipitation of TE were therefore conducted with cultured
dermal fibroblasts from III.1 and IV.4 to determine whether
any protein abnormality could be detected in these families.
An abnormal, 120 kDa protein was detected in both III.1 and
IV.4 (Fig 3A) but not in normal control fibroblast samples (not
shown). A corresponding decrease of normal TE protein
was also observed in III.1 and IV.4 cells (Fig 3A).
Figure 1
Clinical characterization of family cutis laxa (CL)-1. (A) Prematurely
redundant and sagging facial skin of the proband III.1 at age 40 y. (B)
The pedigree of CL-1 indicates autosomal dominant inheritance.
Hatched symbols indicate individuals (I.2, II.9, and III.11) who were
reportedly affected but were not available for examination. Small dia-
monds (IV.2 and IV.3) indicate miscarriages; large diamonds denote
multiple unaffected individuals within the same generation. (C) Poste-
rioanterior (PA) chest X-ray (viewed in AP position) of III.1 shortly before
lung transplantation at the age of 51 y. Hyperexpanded lung fields in-
dicate emphysema. Bilateral basal shadows reveal lung fibrosis. Note
the enlarged left pulmonary artery along the left heart border demon-
strating pulmonary hypertension. (D) Inelastic skin and generalized CL
in individual IV.4 at birth.
Figure 2
Histological and electron microscopic
evaluation of dermal elastic fibers in
patient III.1. (A) Hematoxylin–eosin stain-
ing of a skin section shows metachromat-
ic, fragmented, and clumped (arrows)
elastic fibers. (B) Elastic van Giesson
(EVG) staining of a skin section from III.1
indicates disorganization of elastic fibers
in the upper (arrows) and deep (arrow-
heads) dermis. (C) EVG staining of a
control skin section shows normal, can-
delabra-like organization of elastic fibers
in the papillary dermis (arrows). Transmis-
sion electron microscopy of dermal elas-
tic fibers (El) in III.1 (D) demonstrates
diminished microfibrillar component (ar-
rows) on the periphery of elastic fibers
compared with a normal control (E). Col-
lagen bundles (Col) appear normal. Mag-
nification bars are 100 mm (A–C) and 2 mm
(D–E), respectively.
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To investigate whether a transcript of the abnormal 120
kDa protein was present in CL-1, total RNA was blotted with
an elastin cDNA H-11 probe (Olson et al, 1995), which
identified an abnormal transcript of 5 kb (Fig 3B). To study
the structure of the mutant elastin mRNA in family CL-1, a
30-RACE (rapid amplification of complementary DNA ends)
experiment was conducted using an exon 30-specific
oligonucleotide primer. A mutation-specific 30-RACE prod-
uct was recovered from the samples obtained from indi-
viduals III.1 and IV.4 (Fig 3C) and was found to contain
exons 30, 31, 33, 9, 10, and 452 bp of intron 10 using direct
sequence analysis. This product lacked exon 32, which is
normally subject to high-frequency alternative splicing (sup-
plemental data, Fig S1).
To characterize the entire mutant open reading frame, a
mutation-specific downstream oligonucleotide primer was
designed complementary to the junction of exons 33 and 9.
Sizes and direct DNA sequences of amplification products
between this mutant oligonucleotide and upstream se-
quences suggested the following structure of the mutant
message: exons 1–33, 9–33, 9, 10, and 452 bp of intron 10
(Fig 4A). This structure was further confirmed by RT-PCR
experiments specific for each duplicon (supplemental data).
Nucleotides 3–65 of intron 10 encoded a 21 amino acid C-
terminal missense peptide sequence before ending in a
stop codon. The mutant mRNA had a 4014 bp open reading
frame and encoded a protein with a predicted molecular
weight of 116 kDa, similar to that observed for the mutant
Figure 3
Abnormal tropoelastin (TE) and elastin
mRNA in cutis laxa (CL)-1. (A) Skin fib-
roblasts from affected individuals III.1 and
IV.4 were used to assess TE synthesis by
metabolic labeling and immunoprecipita-
tion. In addition to normal TE (68 kDa),
a prominent 120 kDa protein (arrow)
was detected in CL-1 samples only. Note
that fibronectin (FN) binds directly to the
immunoprecipitation matrix and thus is
present without the use of a primary an-
tibody (Kuusela et al, 1984). Molecular
weight marker positions are shown in ki-
lodaltons (kDa). (B) Total RNA was isolat-
ed from fibroblasts from CL patients III.1 and IV.4 and a normal control (CON) and was analyzed by RNA-blot analysis using human elastin (Olson et
al, 1995) and b-actin cDNA as probes. In addition to the normal 3.5 kb elastin mRNA (elastin), fibroblasts from patients III.1 and IV.4 also contained a
5 kb elastin mRNA (arrow). Molecular weight marker positions are shown in kilobases (kb). (C) Total mRNA from III.1 and a normal control was
analyzed by 30 rapid amplification of cDNA ends (30-RACE) using an upstream gene-specific primer complementary to exon 30. The mutation-
specific 30-RACE product (arrow) was sequenced to determine the structure of the 30-end of the mutant mRNA. Molecular weight marker positions
are shown in base pairs.
Figure 4
A tandem duplication in patients III.1
and IV.4. (A) Domain structure encoded
by the normal elastin message is com-
pared with that of the mutant mRNA de-
tected in the cutis laxa (CL)-1 family. TE
consists of alternating hydrophobic do-
mains (open) and cross-linking domains
(diagonally hatched), flanked by an N-ter-
minal signal peptide and a C-terminal
cysteine-containing, charged peptide
(horizontally hatched). Exons 23 and 32
(asterisks) are normally subject to high-
frequency alternative splicing. In the mu-
tant mRNA, a 452 bp segment of intron 10
is present (shaded) that generates a mis-
sense peptide sequence encoded by the
first 63 nucleotides. A portion of this
unique sequence (underlined) was used
to raise a mutant-specific polyclonal rab-
bit antibody. Note that rather than being a
simple tandem duplication, the mutant
mRNA is a product of a complex rear-
rangement, a duplication of the region
encoded by exons 9—33; a third copy of
exons 9–10 and intron 10 is added to the
end of the mRNA. (B) PCR amplification of
the breakpoint region from genomic DNA of a normal control (CON) and of CL patients III.1 and IV.4 using a sense primer complementary to intron 32
and an antisense primer complementary to intron 9. Size standard positions are shown in kilobase pairs. Panel C. Sequence analysis of the
breakpoint-specific genomic PCR product identified a chimeric intron consisting of 155 bp of intron 33 and 95 bp of intron 8 (double arrows). The
locations of exons 33 and 9 (boxes) and of the amplification primers (arrows) are indicated. (D) Southern blot analysis of the duplication breakpoint
region. Genomic DNA samples from a normal control (CON) and from CL patient III.1 were digested with restriction enzymes BamHI, EcoRI, and
HindIII. DNA fragments were subjected to Southern blot analysis using a breakpoint-specific PCR product (shown in panel B) as a probe. Size
standard positions are shown on the left in kilobases. In addition to fragments identical to the control, duplication-specific 6, 5, and 5 kb fragments
were detected in BamHI, EcoRI, and HindIII digests, respectively (arrowheads).
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TE protein. Alternative splicing patterns were not altered by
the tandem duplication (supplemental data).
To verify the presence of the duplication at the DNA level,
the breakpoint region from genomic DNA of patients III.1
and IV.4 was amplified using oligonucleotide primers com-
plementary to introns 32 (sense) and 9 (antisense) (Fig 4B).
Direct DNA sequencing of this 507 bp product demonstrat-
ed that the duplication junction was 155 bp downstream of
the 50-end of intron 33 and 95 bp upstream of the 30-end of
intron 8 creating a hybrid intron of 250 bp (Fig 4C). The two
introns did not share significant homology with each other,
and database searching did not indicate any common re-
petitive DNA sequence in either intron 8 or 33. Both introns
lacked topoisomerase I and II cleavage consensus se-
quences at the duplication junction positions.
To provide further evidence of a chromosomal DNA du-
plication, genomic DNA from patient III.1 and a normal
control was analyzed using Southern blot analysis. A 507 bp
genomic PCR product containing the duplication breakpoint
was used as a probe. Mutation-specific hybridization sig-
nals were found in samples digested with a variety of re-
striction enzymes (Fig 4D). The clean background obtained
with this probe further supports our earlier finding in that
introns 33 and 9 are free of common repetitive sequences.
To demonstrate disease specificity of the observed du-
plication to family CL-1, 136 normal control individuals
including ten donors from England were screened for the
presence of the breakpoint-specific PCR products and
were found to be negative for the duplication.
In retrospect, the presence of a genomic duplication in
CL-1 explains why direct sequence analysis of genomic
amplimers containing individual exons failed to identify this
mutation. In this assay, both the mutant and normal alleles
served as amplification templates, generating products that
were identical in sequence. Thus, the duplication escaped
detection because of a technique based on screening for
sequence differences.
The synthesis of the duplicated TE molecule was inves-
tigated using immunoprecipitation and western blotting. A
monoclonal TE antibody was used to immunoprecipitate TE
from cell lysates and conditioned media of confluent cul-
tures of fibroblasts derived from III.1, IV.4, and a normal
control. The immunoprecipitates were then analyzed by
immunoblotting using a polyclonal anti-human elastin anti-
body (Fig 5). Cell lysates of CL cells showed the presence of
both normal and mutant TE, confirming the results of our
earlier metabolic labeling experiments (Fig 3A). No band at
the molecular weight of the mutant product was seen in the
control cell lysate. In the conditioned media, a small amount
of the mutant product was also observed, indicating that
some of the aberrant TE protein was secreted.
Since the mutant TE contained a unique and abnormal
extra coding region, immunofluorescence experiments
were conducted to determine whether the mutant TE could
be localized in the fibroblast cultures. For these experi-
ments, a polyclonal rabbit antibody was raised against a
peptide in the unique C-terminal sequence encoded by in-
tron 10 (Fig 4A). Although the antibody did not recognize
either the mutant protein or any other non-specific proteins
in immunoblot experiments, both the crude serum and an
affinity-purified preparation recognized the protein by indi-
rect immunofluorescent staining of fibroblast cultures.
Permeabilized, control fibroblasts showed only weak back-
ground staining when incubated with the mutant TE-specific
intron 10 antibody (Fig 6A). In contrast, permeabilized fib-
roblast cultures from the CL patient III.1 showed strong
intracellular staining (Fig 6B). The staining pattern was pun-
ctate and peri-nuclear consistent with intracellular organ-
elles of the secretory pathway. When cultures were grown to
post-confluency and left non-permeabilized, control cells
were again negative for the intron 10 antibody (Fig 6C),
whereas faint fibrillar staining was seen in CL cultures, in-
dicating the presence of the mutant protein product in the
extracellular matrix (ECM) (Fig 6D). An extensive network of
filamentous staining was seen with the anti-TE antibody
surrounding both control and CL cells, a pattern typical of
elastic fibers assembled by cultured fibroblasts (Fig 6E,F).
Discussion
This study demonstrates that a partial tandem duplication
in ELN causes autosomal dominant CL with severe chronic
obstructive pulmonary disease (COPD). The following lines
of evidence support the conclusion that this duplication is
the disease-causing defect: (1) both affected individuals
studied in the family carried the same duplication; (2) the
duplication was absent in 136 normal control individuals; (3)
the gene defect resulted in a major change in the reading
frame and in the synthesis of mutant TE with partial ECM
incorporation and partial intracellular retention of the ab-
normal protein; and (4) tissue samples from CL patients with
the ELN duplication contained abnormal elastic fibers as
characterized by a lack of association of the amorphous
elastin with microfibrillar components of the fiber.
Detailed clinical investigations identified early-onset em-
physema in two members of the family, III.1 and IV.4, which,
in III.1, culminated in end-stage respiratory failure requiring
a bilateral lung transplant. In addition to carrying an autos-
omal dominant mutation in ELN, both III.1 and IV.4 had two
additional risk factors for COPD: smoking and the a-1 an-
titrypsin M/Z genotype. Although smoking is an established
risk factor of COPD, the a-1 antitrypsin M/Z genotype,
which has a frequency of 5% in Northern Europeans, con-
Figure5
Partial secretion of mutant tropoelastin (TE) in dermal fibroblasts.
TE was immunoprecipitated from cell lysates and conditioned media
from cultured skin fibroblasts. The protein was detected by western
blotting using a different anti-TE antibody. The larger, mutant protein
was detected in the lysate and media (arrows), indicating that the mu-
tant protein was present in the cell and secreted into the medium. The
presence of the mutant protein apparently did not affect the synthesis
and secretion of the normal TE. Standard sizes and the calculated size
of TE are shown in kilodaltons to the left.
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fers only a modest relative risk (1.5) of COPD (Dahl et al,
2002). Moreover, smoking status does not appear to inter-
act with the M/Z genotype to decrease lung function (Dahl
et al, 2002). Only a minority of smokers and M/Z heterozy-
gotes develop emphysema, which usually occurs after the
fourth decade of life. Thus, the primary cause of early and
progressive COPD in family CL-1 is the elastin gene muta-
tion that our studies uncovered, with smoking and reduced
a-1 antitrypsin levels exacerbating an existing lung disease.
Severe emphysematous lung disease is frequently asso-
ciated with autosomal recessive forms of cutis laxa (ARCL)
and leads to significant mortality in infancy (Beighton, 1972).
One form of ARCL associated with infantile lethal lung dis-
ease is caused by a homozygous mutation in the FBLN5
gene (Loeys et al, 2002). In contrast, ADCL is generally de-
scribed as a milder disorder with little systemic pathology
(Beighton, 1972). Thus, our studies have identified COPD as
a newly recognized feature of ADCL caused by ELN de-
fects, and establish ELN as a candidate gene for the genetic
risk of COPD. Furthermore, these findings indicate the im-
portance of lung function testing in the clinical management
of ADCL patients and of counseling against smoking or
other lifestyle choices that may contribute to the deteriora-
tion of lung function.
Previous studies have described small in-frame deletions
and insertions in the elastin gene (Urban et al, 2000; Urban
et al, 2001), some of which were shown to be unrelated to
disease (Urban et al, 2001). Most of these variants were
caused by duplication or deletion of repeated peptide seg-
ments. Interestingly, neither the length of individual exons
(particularly those encoding hydrophobic domains) nor the
number of exons constituting the elastin open reading frame
was conserved in vertebrate evolution (Boyd et al, 1991). In
fact, progressive loss of exons was demonstrated in the
evolution of primates (Szabo et al, 1999). Furthermore, mul-
tiple exons were shown to be alternatively spliced, resulting
in a normal size heterogeneity of TE (Parks and Deak, 1990).
Taken together, these observations indicate that in contrast
to fibrillar collagens, where the length of the individual pro-
collagen polypeptides is crucial for the assembly of func-
tionally competent collagen fibrils (Byers, 2001), the length
of TE monomers is not critical for the deposition of func-
tional elastic fibers. Despite relatively little constraint in TE
length, the duplication mutation in ELN reported in this
study leads to a severe form of dominant CL, indicating that
excessive differences in the size of TE monomers may be
detrimental to elastic fiber function.
Analysis of TE synthesis and secretion in fibroblasts by
immunoprecipitation experiments indicated that the major-
ity of duplicated mutant protein was associated with the cell
layer, with a relatively small amount being secreted into the
medium. Immunostaining of cultured CL fibroblasts using a
mutant-specific antibody confirmed this finding in that mu-
tant TE was partially retained in an intracellular compart-
ment and partially incorporated into a fibrillar ECM. These
results suggest that both inefficient secretion and the bind-
ing of mutant TE to the ECM may contribute to the observed
scarcity of mutant TE in conditioned media. Notably, se-
cretion and matrix incorporation of normal TE was not
impaired, as indicated by our immunoprecipitation and
immunostaining experiments, and no quantitative or qual-
itative defects of elastic fibers were noted in vitro.
All three ADCL mutations described in ELN to date (Ta-
ssabehji et al, 1998; Zhang et al, 1999) are caused by single
nucleotide deletions in exons 30 or 32. These frameshift
Figure 6
Immunofluorescence localization of the mutant tropoelastin (TE) in
dermal fibroblasts. Subconfluent cultures control (A) and cutis laxa
(CL) patient III.1 (B) fibroblasts were fixed and permeabilized for intra-
cellular localization of the mutant TE protein using the intron 10 anti-
body. Whereas only background staining was seen in the control cells
(A), a prominent, punctate, peri-nuclear staining was seen in the patient
fibroblasts (B). Post-confluent fibroblast cultures from control (C) and
CL-1 patient III.1 (D) were fixed and stained with the intron 10 antibody
(specific for the mutant protein). Controls were negative (C), whereas
the extracellular matrix of CL cells was positive for the mutant protein
(D). Nuclei of control cells were counterstained to demonstrate the
presence of the cell layer because staining with the intron 10 antibody
was negative. Post-confluent fibroblast cultures from control (E) and
CL-1 patient III.1 (F) were fixed and stained with an anti-TE antibody
(recognizing both normal and mutant proteins). The abundance and
intensity of elastic fibers were similar in both patient and control cul-
tures. To indicate cell density, nuclei were also stained.
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mutations, depending on the alternative splicing of exon 32,
may result in mRNA with a 30-terminally extended open
reading frame. The duplicated mRNA described in this
study shares two features with the mutant mRNA described
previously in that; (1) there is a missense peptide sequence
located at the C-terminus of the predicted mutant proteins,
and (2) none of the predicted mutant proteins contains an
intact C-terminal domain encoded by exon 36. Either one of
these features, or both together, may contribute to a dis-
ruption of normal elastic fiber structure. For example, in vitro
results have demonstrated that the C-terminal domain,
which contains only 2 cysteines in elastin and a positively
charged RKRK motif, is important for an interaction of TE
with microfibril-associated glycoprotein, MAGP-1 (Brown-
Augsburger et al, 1994). Antibodies raised against the C-
terminal domain of TE inhibited elastin deposition (Brown-
Augsburger et al, 1996) but deletion of this region permitted
association of recombinant TE with ECM (Kozel et al, 2003).
Although the effect of C-terminal missense peptides on
elastic fiber assembly or stability has not yet been inves-
tigated, such hydrophilic sequences may predispose the
normally hydrophobic elastin polymer to proteolytic attack.
Both a-1 antitrypsin M/Z genotype and smoking cause de-
creased elastase inhibitor levels (Gadek et al, 1979; Dahl
et al, 2002), leading to an imbalance of elastase/elastase
inhibitor levels known to be critical in the pathogenesis of
COPD. Extreme sensitivity to cigarette smoking and to the
M/Z genotype supports the hypothesis that incorporation of
mutant TE into the elastic fibers in this CL family results
in increased susceptibility to degradation by elastases. The
progressive nature of CL and COPD in family CL-1 further
corroborates this elastase-susceptibility hypothesis.
Histological and electron microscopic analyses of skin
and bronchial biopsy specimens from III.1 showed quanti-
tatively normal but qualitatively abnormal elastic fibers.
Significantly, electron micrographs indicated a lack of mi-
crofibrils around the periphery of the elastic fibers. Micro-
fibrils are critical for connecting elastic fibers to cells (Davis,
1993) and for providing mechanical coupling and key sig-
nals for tissue development, integrity, and function (Bunton
et al, 2001). Although our studies do not provide a detailed
mechanistic explanation for the loss of microfibrillar content
that we observed, we hypothesize that incorporation of ab-
normal TE could result in a dominant disruption of the el-
astin–microfibrillar interaction, leading to a defect in elastic
fiber function through a dominant-negative mechanism. Al-
ternatively, increased proteolytic degradation of elastin as
discussed previously may also result in the loss of micro-
fibrillar elements in CL.
Methods
Patient samples and cell lines Dermal fibroblast cultures were
established from punch biopsy specimens obtained from III.1 (CL-
1) at the age of 51 y and IV.4 (CL-1) age 24 y as well as a normal
control individual age 31 y following informed consent. Family CL-1
was of English ancestry. Fibroblasts were maintained in Dulbecco’s
modified Eagle medium supplemented with 10% fetal bovine serum
unless indicated otherwise. Skin and bronchial biopsy specimens
were also taken from III.1 at the same time for histology and elec-
tron microscopy. Control DNA samples were isolated from blood
samples of normal, unrelated volunteer participants in our study.
The racial composition of this normal panel of 136 individuals was
as follows: 61 Caucasian (including ten individuals from England to
match the ethnicity of family CL-1), 40 Asian, seven Pacific Islander,
three African, 24 more than one race, and one unknown. This study
was conducted according to the Declaration of Helsinki and was
approved by the Human Studies Committees of the University of
Hawaii and of the Washington University in St Louis.
DNA isolation, direct sequence analysis, and isolation of the
duplication breakpoint After nuclear isolation, DNA was purified
by proteinase K digestion and phenol extraction (Herrmann and
Frischauf, 1987). Each exon of ELN with flanking intronic sequenc-
es was amplified using PCR as described earlier (Urban et al,
1999). Amplimers were directly sequenced on both strands using
the BigDye dye terminator cycle sequencing chemistry (Applied
Biosystems, Foster City, California) and a model 310 Genetic
Analyzer (Applied Biosystems). A breakpoint-specific PCR product
was recovered using 100 ng of genomic DNA in an amplification
reaction with a sense primer complementary to intron 32 50-
TGCAGGCAGAAAGTGATGAG-30 and an antisense primer com-
plementary to intron 9 50-GCCTCAGTCTCCCAAAGCAA-30. The
resulting 507 bp product was then subjected to direct DNA se-
quence analysis. The same PCR assay was used to screen DNA
samples from 136 unrelated, normal control individuals.
Southern and RNA blot analyses Southern and RNA blot anal-
yses were conducted using standard techniques as previously
described (Olson et al, 1995; Urban et al, 2000).
SMART RACE and cloning of the mutant mRNA Total RNA (1
mg) from individuals III.1, IV.4, and a normal control was reverse
transcribed using a SMART RACE cDNA Amplification Kit (Clon-
tech, Palo Alto, California). The RT reaction mixture was used as
the template for primary PCR with one human TE exon 30-specific
primer E30F1 50-GCCTAGTGGGAGCCGCTGGGCTCGGAG-30 and
a universal primer mix. A secondary PCR was performed using
another exon 30-specific primer E30F2 50-GAGTTCCAGGTGTT
GGGGGCCTTGGAG-30 and a nested universal primer. PCR prod-
ucts were separated on the 1.2% agarose gel to display the ab-
normal bands, which were purified with a Gel Extraction kit
(Qiagen, Valencia, California) and further cloned using a TOPO TA
Cloning kit (Invitrogen, Carlsbad, California) for sequencing.
Metabolic labeling, immunoprecipitation, and western blot-
ting Fibroblasts from the CL patients or a normal control individual
were plated in six-well tissue culture plates at an initial density of
2  105 per well and used at 2 d post-confluency. For autoradi-
ography, each well of cells was metabolically labeled with 50 mCi of
[4,5-3H]-L-leucine (1 mCi per mL; ICN Pharmaceuticals, Irvine,
California) in 1 mL of leucine-free medium containing 5% dialyzed
fetal bovine serum for 4 h. Media were collected and cell layers
were washed three times with cold phosphate-buffered saline
(PBS) prior to lysis in 1 mL of cold lysis buffer (25 mM Tris-HCl (pH
7.5), 5 mM EDTA (pH 7.5), 250 mM NaCl, 0.1% Triton X-100) con-
taining protease inhibitors. TE was immunoprecipitated from both
media and lysate samples using a monoclonal (BA-4) anti-elastin
antibody (Wrenn et al, 1986) and Staphylococcus aureus (Pansor-
bin cells) to collect the immune complexes. Immunoprecipitates
were separated by sodium dodecyl-sulfate polyacrylamide gel
electrophoresis fixed, treated with EN3HANCE, (New England
Nuclear, Boston, Massachusetts) and exposed to X-ray film. For
immunoblotting, media on each well of cells were changed to
1.25 mL of fresh, unlabeled media for 24 h. Media and lysates were
collected and immunoprecipitated as described above, and then
separated by sodium dodecyl-sulfate polyacrylamide gel elect-
rophoresis and transferred to nitrocellulose. A polyclonal antibody
raised against recombinant human TE (a gift from Dr Robert Mec-
ham) was used to detect normal and mutant TE proteins on the
blot. Donkey anti-rabbit horseradish peroxidase-conjugated F(ab0)2
(Amersham Life Science, Arlington Heights, Illinois) and ECL de-
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tection reagents (Pierce, Rockford, Illinois) were used according to
the manufacturers’ directions.
Mutant-specific antibody and immunoﬂuorescent staining A
polyclonal rabbit antiserum was raised against a C-terminal pep-
tide from the mutant TE allele (MQLSGQRADGRDSPTTFWPR) en-
coded by an intron 10 sequence in the mutant mRNA (Fig 4). The
peptide was chemically synthesized and conjugated to keyhole
limpet hemocyanin using an amino group-specific chemistry. An-
tisera were assayed against the peptide using an ELISA and were
further purified using affinity chromatography using immobilized
peptide antigen.
For intracellular immunolocalization of TE, confluent cultures of
III.1 and control fibroblasts in four-well LabTek Chamber Slides
(Nunc no. 177437, Thomas Scientific, Swedesboro, New Jersey)
were washed with PBS and fixed with 2% paraformaldehyde in
PBS for 30 min. Following several washes in PBS, reactive alde-
hydes were quenched by incubating the cells in 50 mM NH4Cl for
30 min. The cell layers were then rinsed in PBS containing 1%
bovine serum albumin and 0.1% saponin and further permeabilized
for 2  15 min in the saponin permeabilization buffer. The perm-
eabilized cells were then incubated with primary antibody for 1 h at
room temperature. All subsequent antibody dilutions and washes
were with the permeabilization buffer. After washing 4  5 min, the
cells were incubated with goat anti-rabbit fluorescein-conjugated
IgG (Cappel, West Chester, Pennsylvania) diluted 1:200 for 1 h.
Nuclei were stained with propidium iodide to visualize the cell layer
in some experiments. Cell layers were then washed 4  5 min, then
rinsed once with PBS, before mounting in 50% glycerol in PBS
containing 1 mg per mL p-phenylenediamine, and visualized with
an Axioskop microscope (Zeiss, Thornwood, New York). To inves-
tigate the formation of extracellular elastic fibers, post-confluent
III.1 and control fibroblast cultures were treated as described
above, but with the exclusion of saponin. For localization of normal
TE in the matrix, the monoclonal BA-4 antibody was used followed
by a goat anti-mouse fluorescein-conjugated IgG (Cappel).
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